A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis

This case study reports on a 46-year-old female with severe atopic dermatitis and persistent subtotal alopecia areata (AA), who experienced unexpected successful treatment of AA with tralokinumab, an IL-13 blocker. Despite previous treatments, her dermatitis was poorly controlled, and AA showed no response to a class IV topical steroid. The patient declined JAK inhibitors due to monitoring requirements and opted for tralokinumab, receiving a loading dose followed by regular injections. Her dermatitis improved significantly within 2 months, and complete hair regrowth was observed after 7 months. This case highlights the potential role of type 2 inflammation in AA's pathogenesis and suggests that targeting IL-13 may promote disease remission, warranting further research into its therapeutic implications.